Additionally, the company is asking for the associated lawsuits to be dismissed, under a 702 judgment, based on the adequacy of the FDA-approved product labeling and the lack of admissible expert testimony on general causation. This is a common defense tactic in mass litigation, like this MDL for Ozempic and other GLP-1 drugs
#2: MEDVi GLP-1 ($119$499/mo): Best for immediate access , featuring a 3-minute average approval time and same-day prescriptions
But again, Rahul, like you're saying it's like, I think right now protein's in a point where, where it's got such great marketing that like you slap protein on anything no matter what else is in that product
Image Credit: Tatjana Baibakova/Shutteratock
Frailty and sarcopenia in patients pre- and post-liver transplant